Lupin Secures U.S. FDA Approval for Generic Modafinil Tablets
Lupin Ltd 路 Press Release 路 04 Sept 2026, 11:12 pm
Lupin Secures U.S. FDA Approval for Generic Modafinil Tablets Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP (100 mg and 200 mg) on 4th Sep'26. The product is a generic equivalent of Nuvo Pharmaceuticals' Provigil Tablets, indicated to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea, or shift work disorder. According to IQVIA MAT Jul'26 data, Modafinil Tablets had estimated annual sales of USD 70.7 million in the U.S. market.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
